Conventional type 1 dendritic cells (cDC1) in cancer immunity

Peng Liu; Liwei Zhao; Guido Kroemer; Oliver Kepp

doi:10.1186/s13062-023-00430-5

Conventional type 1 dendritic cells (cDC1) in cancer immunity

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

12 Citations (Scopus)

Résumé

Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

langue originale	Anglais
Numéro d'article	71
journal	Biology Direct
Volume	18
Numéro de publication	1
Les DOIs	https://doi.org/10.1186/s13062-023-00430-5
état	Publié - 1 déc. 2023

Accès au document

10.1186/s13062-023-00430-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{a0131889d824464297356da1f4882c7a,

title = "Conventional type 1 dendritic cells (cDC1) in cancer immunity",

abstract = "Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.",

author = "Peng Liu and Liwei Zhao and Guido Kroemer and Oliver Kepp",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

day = "1",

doi = "10.1186/s13062-023-00430-5",

language = "English",

volume = "18",

journal = "Biology Direct",

issn = "1745-6150",

number = "1",

}

TY - JOUR

T1 - Conventional type 1 dendritic cells (cDC1) in cancer immunity

AU - Liu, Peng

AU - Zhao, Liwei

AU - Kroemer, Guido

AU - Kepp, Oliver

PY - 2023/12/1

Y1 - 2023/12/1

N2 - Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

AB - Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85175688907&partnerID=8YFLogxK

U2 - 10.1186/s13062-023-00430-5

DO - 10.1186/s13062-023-00430-5

M3 - Review article

C2 - 37907944

AN - SCOPUS:85175688907

SN - 1745-6150

VL - 18

JO - Biology Direct

JF - Biology Direct

IS - 1

M1 - 71

ER -